Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PankoMab-GEX in Patients With Advanced, TA-MUC1 Positive Solid Malignancies Who Are Not Longer Eligible for Standard Therapy.

Trial Profile

Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PankoMab-GEX in Patients With Advanced, TA-MUC1 Positive Solid Malignancies Who Are Not Longer Eligible for Standard Therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Anti-TA-MUC1 monoclonal antibody (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 07 Jun 2016 Results published in the European Journal of Cancer
    • 16 Oct 2013 Results published in Glycotope media release, and reported at this year's European Cancer Congress (ECCO 17), according to the media release.
    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top